| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D277-82
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D277-82 |
| filingDate |
2004-06-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_903c59a9f5c756585394ecbba0db942a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bceb8186457a6e057f6dcdb2fa68be65 |
| publicationDate |
2006-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20060012031-A |
| titleOfInvention |
2-aminobenzothiazole as cannabanoid receptor 1 inverse agonist |
| abstract |
The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof for use as a therapeutically active substance. This compound is useful for treating and / or preventing diseases associated with the modulation of CB1 receptors:n n n Formula In n n n n n n n Wheren n n R 1 , R 2 , R 3 , R 3a and R 3b are as defined in the specification and claims. |
| priorityDate |
2003-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |